Phaseline

Companies › Incyte Biosciences International Sàrl

Incyte Biosciences International Sàrl: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ponatinib
Bcr/Abl fusion protein inhibitor
ABL1, BCRPhase 1Acute Myeloid LeukemiaFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03934372PonatinibPhase 1Acute Myeloid LeukemiaOncologyFeb 2028

From the company's SEC filings

Cash of $3.3bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Targets

ABL1 (1) BCR (1)

Companies with the same targets

Ascentage Pharma Group Il-Yang Pharm. Takeda Enliven Therapeutics Novartis Taiho Pharmaceutical Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Otsuka Bayer

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.